Measles clinical trials
The registry lists 134 studies for Measles across more than 10 countries. 17 are recruiting or about to start. 85 of them are mainly about Measles (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Measles studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (23) · Merck Sharp & Dohme LLC (19) · Bandim Health Project (12) · Sanofi Pasteur, a Sanofi Company (7) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (7) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Johns Hopkins Bloomberg School of Public Health (3) · Centers for Disease Control and Prevention (3)
What is being tested here
Drugs under test in Measles studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Measles Vaccination at Health System Contacts · Bandim Health Project
- Dec 2026the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines · China National Biotec Group Company Limited
- Sep 2027Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients · Children's Mercy Hospital Kansas City
Who these studies take
Of the 9 Measles studies recruiting now, 1 (11%) set no upper age limit and 8 (89%) stop at 75 or younger. 7 (78%) take children under 18. 1 (11%) are for women only and 0 (0%) for men only; 6 (67%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (33%) | 3 (33%) |
| 18 | 5 (56%) | 4 (44%) |
| 30 | 4 (44%) | 3 (33%) |
| 40 | 3 (33%) | 3 (33%) |
| 50 | 2 (22%) | 2 (22%) |
| 65 | 2 (22%) | 2 (22%) |
| 75 | 2 (22%) | 2 (22%) |
| 85 | 1 (11%) | 1 (11%) |
Across all 134 studies, recruiting or not: 84% stop at 75 or younger and 82% at 65; 88% take children; 2% are for women only and 1% for men only; 85% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Measles studies take
Of 16 phase 3 interventional studies under Measles, half reached primary completion within 13 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 3 | 13 mo8–24 · 16 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
Studies
Recruiting first, then most recently updated. Showing 50 of 134. Browse all 134 → or search them.
- The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron DeficiencyRecruitingNCT06816524Not applicable1 country
- Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation PatientsRecruitingNCT07195032Phase 41 country
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 36 countries
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 31 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT073388511 country
- Unravelling the Measles Paradox (MISIA)RecruitingNCT072675851 country
- Unravelling the Measles Paradox in ChildrenNot yet recruitingNCT069236311 country
- Prospective Clinical Registry for Evaluation of Exanthematous Infections and CoinfectionsNot yet recruitingNCT07112846
- Measles Vaccination at Health System ContactsEnrolling by invitationNCT04220671Phase 41 country
- Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 MonthsNot yet recruitingNCT06815835Phase 31 country
- Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden SettingsRecruitingNCT06667206Phase 21 country
- Measles and BCG Vaccines for Mother and ChildRecruitingNCT04899765Phase 41 country
- Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster VaccinationRecruitingNCT05894395Phase 31 country
- Co-administration Study of OCV, TCV and MRNot yet recruitingNCT05771779Phase 3
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingNCT05952505Phase 41 country
- Induction of Immunity Against Measles in Pediatric Liver Transplant RecipientsRecruitingNCT01770119Phase 41 country
- Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in SenegalTerminatedNCT058609201 country
- Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 MonthsCompletedNCT06387511Not applicable1 country
- Investigation of Immune Amnesia Following Measles Infection in Select African RegionsCompletedNCT061539792 countries
- Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRCompletedNCT02325310Phase 41 country
- Trial of Additional Measles Vaccine to Reduce Child MortalityCompletedNCT01644721Phase 41 country
- Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.CompletedNCT01668745Phase 41 country
- Predictors of Measles Vaccine Hesitancy in New York StateCompletedNCT073730931 country
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 31 country
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 24 countries
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedNCT06331702Phase 41 country
- Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of AgeCompletedNCT03071575Phase 41 country
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 25 countries
- Barriers and Facilitators to MMR Vaccination Among Healthcare WorkersCompletedNCT064567881 country
- A Tool Kit to Improve Vaccine Confidence in the PhilippinesActive, not recruitingNCT06218368Not applicable1 country
- Evaluation of Pediatric Measles Cases in 2019: Single-Center ExperienceCompletedNCT056147911 country
- Vaccine Campaign Effects on General Hospital Admissions and Mortality Among ChildrenCompletedNCT03460002Phase 41 country
- Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases ConfirmedCompletedNCT055927561 country
- Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control TrialStatus unknownNCT05803538Not applicable1 country
- Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation TrialCompletedNCT04394689Phase 1/21 country
- Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western KenyaCompletedNCT01878435Not applicable1 country
- Ontogeny of Measles Immunity in InfantsCompletedNCT002409161 country
- The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella VaccineStatus unknownNCT05279248Phase 41 country
- Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)Status unknownNCT05154097
- Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV DrugsCompletedNCT00013871Not applicable2 countries
- A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials GroupCompletedNCT00000815Phase 22 countries
- Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)CompletedNCT00432523Phase 32 countries
- Measles, Mumps, and Rubella (MMR) Immunity in College StudentsCompletedNCT009628191 country
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps VaccineCompletedNCT04364399Phase 41 country
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 37 countries
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 35 countries
- Phase I Trial of Measles Vectored Chikungungya VaccineCompletedNCT03028441Phase 11 country
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedNCT02880865Phase 41 country
- Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and RubellaCompletedNCT03148990Phase 2/31 country